<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785902</url>
  </required_header>
  <id_info>
    <org_study_id>CP2008-1</org_study_id>
    <nct_id>NCT00785902</nct_id>
  </id_info>
  <brief_title>AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation</brief_title>
  <acronym>A</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABLATE Persistent is a prospective, non-randomized multi-center clinical trial to demonstrate
      the safety and effectiveness of the AtriCure Bipolar System for treating persistent atrial
      fibrillation during concomitant on-pump cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The primary efficacy endpoint for this study is the percent of patients free from AF and off Class I and III antiarrhythmic drugs at 9 months.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary safety endpoint is the composite acute major adverse event rate, within 30 days post-procedure or hospital discharge</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy endpoint for this study is the percent of patients free from AF, independent of antiarrhythmic drug status at 9 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary safety endpoint is the composite 9-month post-procedure major adverse event rate.</measure>
  </secondary_outcome>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AtriCure Bipolar System</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is greater than or equal to 18 years of age

          2. Subject has history of persistent atrial fibrillation as defined by the ACC/AHA/ESC
             Guidelines

          3. Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) for one
             or more of the following:

               -  Mitral valve repair or replacement

               -  Aortic valve repair or replacement

               -  Tricuspid valve repair or replacement

               -  Coronary Artery Bypass procedures

          4. Subject's Left Ventricular Ejection Fraction â‰¥ 30%

          5. Subject is able and willing to provide written informed consent and comply with study
             requirements

          6. Subject has life expectancy of at least 1 year

        Exclusion Criteria:

          1. Patients with longstanding and continuous AF in which cardioversion has failed or has
             not been attempted

          2. Previous cardiac ablation including catheter ablation, AV-nodal ablation, or surgical
             Maze procedure

          3. Wolff-Parkinson-White syndrome

          4. Prior cardiac surgery (Redo)

          5. Class IV NYHA heart failure symptoms

          6. Prior history of cerebrovascular accidents within 6 months or at any time if there is
             residual neurological deficit

          7. Documented MI within 6 weeks prior to study enrollment

          8. Need for emergent cardiac surgery (i.e. cardiogenic shock)

          9. Known carotid artery stenosis greater than 80%

         10. LA size greater than or equal to 8 cm

         11. Current diagnosis of active systemic infection

         12. Severe peripheral arterial occlusive disease defined as claudication with minimal
             exertion

         13. Pregnancy or desire to get pregnant within 12-months of the study enrollment

         14. Preoperative need for an intra-aortic balloon pump or intravenous inotropes

         15. Renal failure requiring dialysis or hepatic failure

         16. Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia

         17. Therapy resulting in compromised tissue integrity including: thoracic radiation,
             chemotherapy, long term treatment with oral or injected steroids, or known connective
             tissue disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

